Femme Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
Primary Safety Objective: To confirm the endometrial safety of BZA 20 mg/CE 0.45 mg and BZA 20 mg/CE 0.625 mg based on an endometrial hyperplasia incidence of less than 1% at year 1. Primary Efficacy Objective: To assess the effect of BZA/CE in preventing postmenopausal osteoporosis at year 1 (osteoporosis substudy)
Critère d'inclusion
- Menopause